MedTrace Logo

Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

NCT00396110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3889

Last updated 2006-11-06

No results posted yet for this study

Summary

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C \< 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Ingrid van Geel, MD · AstraZeneca

  • Ingeborg Vosjan, MD · AstraZeneca

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396110 on ClinicalTrials.gov